SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Mimedx Group, Inc. – ‘10-K’ for 12/31/12 – ‘R32’

On:  Friday, 3/15/13, at 5:14pm ET   ·   For:  12/31/12   ·   Accession #:  1140361-13-12765   ·   File #:  0-52491

Previous ‘10-K’:  ‘10-K/A’ on 6/21/12 for 12/31/11   ·   Next:  ‘10-K’ on 3/4/14 for 12/31/13   ·   Latest:  ‘10-K’ on 2/28/24 for 12/31/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/15/13  Mimedx Group, Inc.                10-K       12/31/12   70:10M                                    Broadridge Fin’l So… Inc

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Mimedx Group Inc 10-K 12-31-2012                    HTML   1.04M 
 2: EX-10.54    Material Contract                                   HTML     39K 
 3: EX-10.55    Material Contract                                   HTML     27K 
 4: EX-10.56    Material Contract                                   HTML     96K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     19K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
47: R1          Document and Entity Information                     HTML     48K 
37: R2          Consolidated Balance Sheets                         HTML    126K 
45: R3          Consolidated Balance Sheets (Parenthetical)         HTML     56K 
49: R4          Consolidated Statements of Operations               HTML     70K 
64: R5          Consolidated Statements of Stockholders' Equity     HTML    130K 
39: R6          Consolidated Statements of Stockholders' Equity     HTML     22K 
                (Parenthetical)                                                  
44: R7          Consolidated Statements of Cash Flows               HTML    150K 
34: R8          Consolidated Statements of Cash Flows               HTML     76K 
                (Parenthetical)                                                  
26: R9          Nature of Business                                  HTML     24K 
66: R10         Significant Accounting Policies                     HTML    124K 
51: R11         Liquidity and Management's Plans                    HTML     22K 
50: R12         Acquisition of Surgical Biologics, LLC              HTML     85K 
55: R13         Inventories                                         HTML     33K 
56: R14         Property and Equipment                              HTML     36K 
54: R15         Intangible Assets and Royalty Agreement             HTML     96K 
57: R16         Accrued Expenses                                    HTML     30K 
46: R17         Long-Term Debt                                      HTML     54K 
48: R18         Common Stock Placements                             HTML     36K 
53: R19         Equity                                              HTML    185K 
70: R20         Income Taxes                                        HTML     58K 
60: R21         Related Party Transactions                          HTML     38K 
41: R22         401k Plan                                           HTML     30K 
52: R23         Commitments                                         HTML     30K 
43: R24         Subsequent Events                                   HTML     24K 
20: R25         Significant Accounting Policies (Policies)          HTML    222K 
61: R26         Significant Accounting Policies (Tables)            HTML     65K 
67: R27         Acquisition of Surgical Biologics, LLC (Tables)     HTML     72K 
30: R28         Inventories (Tables)                                HTML     30K 
29: R29         Property and Equipment (Tables)                     HTML     33K 
32: R30         Intangible Assets and Royalty Agreement (Tables)    HTML     96K 
33: R31         Accrued Expenses (Tables)                           HTML     27K 
35: R32         Long-Term Debt (Tables)                             HTML     47K 
19: R33         Equity (Tables)                                     HTML    182K 
58: R34         Income Taxes (Tables)                               HTML     50K 
40: R35         Related Party Transactions (Tables)                 HTML     33K 
42: R36         Commitments (Tables)                                HTML     25K 
23: R37         Nature of Business (Details)                        HTML     21K 
69: R38         Significant Accounting Policies (Details)           HTML    157K 
16: R39         Liquidity and Management's Plans (Details)          HTML     31K 
36: R40         Acquisition of Surgical Biologics, LLC (Details)    HTML    177K 
63: R41         Inventories (Details)                               HTML     38K 
22: R42         Property and Equipment (Details)                    HTML     34K 
28: R43         Intangible Assets and Royalty Agreement (Details)   HTML    122K 
31: R44         Accrued Expenses (Details)                          HTML     31K 
38: R45         Long-Term Debt (Details)                            HTML    116K 
18: R46         Common Stock Placements (Details)                   HTML     70K 
25: R47         Equity (Details)                                    HTML    285K 
17: R48         Income Taxes (Details)                              HTML     95K 
62: R49         Related Party Transactions (Details)                HTML     31K 
21: R50         401k Plan (Details)                                 HTML     32K 
59: R51         Commitments (Details)                               HTML     28K 
24: R52         Subsequent Events (Details)                         HTML     37K 
68: XML         IDEA XML File -- Filing Summary                      XML     94K 
27: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.52M 
10: EX-101.INS  XBRL Instance -- mdxg-20121231                       XML   2.21M 
12: EX-101.CAL  XBRL Calculations -- mdxg-20121231_cal               XML    193K 
13: EX-101.DEF  XBRL Definitions -- mdxg-20121231_def                XML    640K 
14: EX-101.LAB  XBRL Labels -- mdxg-20121231_lab                     XML   2.22M 
15: EX-101.PRE  XBRL Presentations -- mdxg-20121231_pre              XML   1.17M 
11: EX-101.SCH  XBRL Schema -- mdxg-20121231                         XSD    203K 
65: ZIP         XBRL Zipped Folder -- 0001140361-13-012765-xbrl      Zip    225K 


‘R32’   —   Long-Term Debt (Tables)


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v2.4.0.6
Long-Term Debt (Tables)
12 Months Ended
Long-Term Debt [Abstract]  
Long-term Debt
The following table summarizes our long-term debt:

   
  
2012
  
2011
 
$5M Convertible Senior Secured Promissory Notes including  interest at 5% per annum payable quarterly through December 31, 2013, and an additional one time 5% interest charge payable on January 15, 2013 if not repaid by December 31, 2012, collateralized by a first priority lien shared equally with holder of the Convertible Line of Credit with Related Party in all of the patents and intellectual property owned by the Company subordinated to the Convertible Debt related to acquisition for Surgical Biologics intellectual property until repaid. (a)
 $5,313,645  $5,007,732 
         
Convertible Line of Credit with Related Party with 5% interest; principal and interest payable in full December 31, 2012 collateralized by a first priority lien shared equally with holders of Convertible Senior Secured Promissory Notes in all patents and intellectual property of the Company subordinated to the Convertible debt related to the acquisition for Surgical Biologics intellectual property until repaid. (b)
  -   1,342,726 
         
Convertible debt related to acquisition with 4% interest; principal and interest payable in full on July 5, 2012, collateralized by a first priority lien in all the intellectual property owned by Surgical Biologics immediately after the closing. (c)
  -   1,299,315 
         
Total debt
 $5,313,645  $7,649,773 
         
Less unamortized debt discount
  (1,301,203)  (2,480,400)
         
Less current portion
  -   (2,424,786)
         
Long-term portion
 $4,012,442  $2,744,587 

(a) Investors received First Contingent Warrants (25% of amount invested) and Second Contingent Warrants (25% of amount invested) at an exercise price of $.01 per share. In March 2012 a total of 1,250,000 First Contingent Warrants were vested. In July 2012, a total of 1,250,000 Second Contingent Warrants were voided due to the Company share price trading at or above $1.75 for ten consecutive trading days. The additional interest resulting from the beneficial conversion feature, inclusive of the First Contingent Warrants, totaled $2,278,052 which has been recorded as a debt discount that has been and will continue to be charged to interest expense using the effective interest rate over the life of the note.
 
(b) The same terms offered to the Senior Secured Promissory note with regard to Contingent Warrants applied to the Convertible Line of Credit. In March 2012 a total of 325,000 First Contingent Warrants vested. In July 2012, a total of 325,000 Second Contingent Warrants were voided. The additional interest related to the beneficial conversion feature totaled $594,456 and was recorded as a debt discount and charged to interest expense using the effective interest rate over the life of the note. On December 7, 2012, the Chairman and CEO elected to convert his note and accrued interest resulting in the issuance of 1,403,630 shares of MiMedx common stock.
 
(c) Additional financing expense of $437,500 was recorded for the beneficial conversion feature of the convertible notes over the term of the note. In July, 2012, the Company settled the Convertible Promissory Notes by paying approximately $177,000 in cash and issuing 893,267 shares of MiMedx common stock.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
12/31/1310-K,  10-K/A
Filed on:3/15/13
1/15/134
For Period end:12/31/12
12/7/124
7/5/12
 List all Filings 
Top
Filing Submission 0001140361-13-012765   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 12:58:01.1am ET